We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Clears Tykerb for Advanced Metastatic Breast Cancer
FDA Clears Tykerb for Advanced Metastatic Breast Cancer
March 16, 2007
GlaxoSmithKline’s (GSK) kinase inhibitor Tykerb gained FDA approval for use in combination with Roche’s oral chemotherapeutic Xeloda for the treatment of advanced metastatic breast cancer — specifically in tumors that produce an excess of the HER2 protein.